International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:
“At the 2025 WCLC, Dr. Scott Laurie presented updated results from the IND227 study showing that pembrolizumab plus platinum-pemetrexed chemotherapy improved overall survival by 24% versus chemotherapy alone.
Longer follow-up confirmed sustained benefit, and exploratory analyses showed that pembrolizumab monotherapy also trended toward improved survival.
Read more about the results.”
More posts featuring IASLC.